Verastem, Inc. (VSTM) Earnings Call Transcripts

Verastem, Inc.'s Latest Earnings Call - June 23, 2026

In the second quarter of 2026, Verastem, Inc. (VSTM:US) reported significant progress in its clinical development of VS-7375, a selective oral KRAS G12D inhibitor. The company highlighted encouraging preliminary data from the Target-D 101 trial, with a total addressable market exceeding $2.5 billion in the U.S. alone. Management maintained guidance on the rapid advancement of three pivotal Phase III trials expected to begin by the first half of 2027, reinforcing confidence in the drug's potential as a best-in-class treatment option for KRAS G12D mutated cancers.

Reported metrics

Guidance from management

Verastem maintains its guidance on rapid enrollment in Phase II trials and anticipates starting three pivotal Phase III trials by the first half of 2027, reflecting confidence in the development timeline for VS-7375.

What management said

Eric, thanks for the question. We actually haven't really released any details on it yet. As you can imagine, we're in the process of having discussions with others around other partnerships and don't want to impact those. As we get closer to it, we'll give a little more detail, but we're very excited to have agreed with them to do a study together.

Yes. John, I don't know if from a scientific point of view, I'm not aware of any literature on a direct correlation between those 2. I mean CA19-9 is a direct measure of tumor cell mass, not necessarily pancreatic cancer cell size as I keep emphasizing this rather fibrotic reaction that we see a lot in pancreatic cancer. But live cells are the cells that make the enzymes that lead to CA19-9. And I don't know that, fr...

What analysts pressed on

Analysts expressed concerns regarding the competitive landscape and the approval hurdles for the upcoming Phase II and III trials. Questions were raised about the efficacy benchmarks required for accelerated approval and the potential impact of emerging data on the treatment landscape.

Main topics on the call

• Clinical Development Progress — Verastem has enrolled over 150 patients in the Target-D 101 Phase I/II trial, with plans to initiate three registration-directed Phase II trials in pancreatic, colorectal, and non-small cell lung cancers by mid-2026. CEO...
• Emerging Efficacy Signals — Preliminary data indicate dose-dependent antitumor activity at both 600 mg and 900 mg doses, with the latter showing promising results in combination with standard therapies. Management noted, "We believe many patients w...
• Safety and Tolerability Profile — Management reported a favorable safety profile for VS-7375, characterized by manageable low-grade adverse events. Dr. Michael Kauffman emphasized, "We've not yet identified significant major safety issues associated with...
• Market Opportunity — The addressable market for VS-7375 is substantial, with approximately 40% of pancreatic cancers and 15% of colorectal cancers harboring the KRAS G12D mutation. Paterson stated, "We have an opportunity to fundamentally al...

Read the full Verastem, Inc. transcript (June 23, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 18 Verastem, Inc. earnings call transcripts on record, spanning January 8, 2020 to August 6, 2026. Based on this history, Verastem, Inc. reports semi-annually. The most recent call on file is dated August 6, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

VSTM

Exchange

NasdaqCM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

18

First call

January 8, 2020

Most recent

August 6, 2026

Reporting cadence

semi-annually